Trevena's TRV027 misses heart failure endpoint

Trevena Inc. (NASDAQ:TRVN) slipped $0.50 to $6.32 on Monday after its TRV027 missed the primary and secondary endpoints in the Phase IIb BLAST-AHF study to treat acute heart failure (AHF). The company did not disclose details, but intends to present the data on May 21 at the European Society of Cardiology's Heart Failure Association meeting.

BLAST-AHF's primary endpoint was a composite of mortality, worsening heart failure, hospital readmission rate, dyspnea and length of hospital stay. The 618-patient trial compared 1, 5 and 25 mg/hour IV TRV027 given continuously for 48-96 hours plus standard therapy vs. placebo plus standard therapy. ...